37th week of 2013 patent applcation highlights part 39 |
Patent application number | Title | Published |
20130236457 | Compositions and Methods Relating to Anti-IGF-1 Receptor Antibodies - The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions. | 2013-09-12 |
20130236458 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-13 AND/OR IL-17 - Engineered multivalent and multispecific binding proteins that bind IL-13 and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 2013-09-12 |
20130236459 | MONOSPECIFIC AND BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES - Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided. | 2013-09-12 |
20130236460 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 2013-09-12 |
20130236461 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 2013-09-12 |
20130236462 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 2013-09-12 |
20130236463 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 2013-09-12 |
20130236464 | ANTI-CLTA4, ANTI-GLUT2 PROTEIN FOR THE TREATMENT OF TYPE 1 DIABETES - The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic β-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic β-cells. | 2013-09-12 |
20130236465 | EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT LACKING EXON - The present invention provides an epidermal growth factor receptor variant-de4 EGFR protein. The variant lacks the fourth exon of the epidermal growth factor receptor, and promotes tumor cell invasion/metastasis. The present invention also provides an encoding gene for the variant and a method of producing the variant by means of recombination technology. | 2013-09-12 |
20130236466 | AMYLOID BETA-DERIVED DIFFUSIBLE LIGANDS (ADDLs), ADDL-SURROGATES, ADDL-BINDING MOLECULES, AND USES THEREOF - The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders. | 2013-09-12 |
20130236467 | MULTISPECIFIC ANTIGEN BINDING PROTEINS TARGETING HGF - The invention relates to combinations of HGF-antagonists with VEGF antagonists, and provides antigen-binding proteins which bind to HGF comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding protein has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof. | 2013-09-12 |
20130236468 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY - The present invention relates to a combination comprising compounds of formula (I): | 2013-09-12 |
20130236469 | VACCINE AGAINST STREPTOCOCCAL INFECTIONS BASED ON RECOMBINANT PROTEINS - An antigenic composition comprises several antigenic components derived from antigens of | 2013-09-12 |
20130236470 | THERAPEUTIC AGENT FOR MALIGNANT TUMORS EXPRESSING MHC CLASS II - Provided is a novel therapeutic agent specific for a malignant tumor expressing MHC class II. The present invention provides an antibody recognizing a protein constituting MHC class II expressed on a malignant tumor, the antibody comprising at least one selected from heavy chain CDR1 (amino acid sequence represented by positions 49 to 54 of SEQ ID NO: 54), heavy chain CDR2 (amino acid sequence represented by positions 69 to 84 of SEQ ID NO: 54), heavy chain CDR3 (amino acid sequence represented by positions 117 to 128 of SEQ ID NO: 54), light chain CDR1 (amino acid sequence represented by positions 46 to 55 of SEQ ID NO: 56), light chain CDR2 (amino acid sequence represented by positions 71 to 77 of SEQ ID NO: 56), and light chain CDR3 (amino acid sequence represented by positions 100 to 108 of SEQ ID NO: 56). | 2013-09-12 |
20130236471 | ANTI IL-36R ANTIBODIES - The present invention relates to anti-IL-36R binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same. | 2013-09-12 |
20130236472 | COMPOUNDS AND MIXTURES FOR INFLUENCING INFLAMMATORY STATES - The invention relates to certain compounds, salts of these compounds and mixtures containing or consisting of two or more such compounds, two or more such salts or one or more such compounds and one or more such salts, each for use in a method for the prophylaxis and/or treatment of inflammation, in particular of inflammation of the skin. | 2013-09-12 |
20130236473 | THERAPEUTIC AGENTS AND PROPHYLACTIC AGENTS FOR SYMPTOMS ACCOMPANYING AUTOIMMUNE DISEASES, INFLAMMATORY DISEASES, ALLERGY DISEASES AND ORGAN TRANSPLANTS - A major object of the present invention is to provide a novel therapeutic or prophylactic agent for at least one disease or symptom selected from the group consisting of autoimmune diseases, inflammatory diseases, allergic diseases, and symptoms accompanying organ transplants; the therapeutic or prophylactic agent artificially controls the activity of IL-6 amplifier, thus controlling immune reactions in living organisms. Another object of the present invention is to provide an immunosuppressant, an inflammatory cytokine production inhibitor, and an IL-6 amplifier inhibitor. | 2013-09-12 |
20130236474 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY - The invention provides methods for increasing or decreasing antibody production in vivo by inhibiting or promoting the activity of fibroblast growth factor-2 (FGF2) respectively. | 2013-09-12 |
20130236475 | METHODS FOR REDUCING ALLERGIES CAUSED BY ENVIRONMENTAL ALLERGENS - Compositions suitable for reducing symptoms of an allergic response to environmental allergens comprising molecules that specifically inhibit the ability of the allergen to bind to mast cells in an animal predisposed to having an allergic response to the allergen and methods for reducing such symptoms comprising contacting a source of the environmental allergen with such compositions. Kits, packages, medicaments, and means of communicating about the compositions and methods are also provided. | 2013-09-12 |
20130236476 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use - The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders. | 2013-09-12 |
20130236477 | Methods for Promoting Reinnervation of Auditory Hair Cells - This invention relates to methods for promoting reinnervation of auditory hair cells, specifically, by inhibiting Repulsive Guidance Molecule a (RGMa), a repulsive axonal guidance molecule that is expressed in the cochlea, or its receptor, neogenin. | 2013-09-12 |
20130236478 | PROCESS FOR THE PREPARATION AND USE OF A BIVALENT VACCINE AGAINST MORPHINE-HEROINE ADDICTION - Provided are bivalent immunogenic composition against morphine-heroin addiction comprising a carrier protein (“CP”) and a morphinic product, wherein the CP and the morphinic product are connected by a spacer-linker arm having a total molecular size of 16-21 Å, and methods of using the same. | 2013-09-12 |
20130236479 | ANTIGEN - The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described. | 2013-09-12 |
20130236480 | TRANSGLUTAMINASE 2 INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS - The present invention relates to TG2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis and to pharmaceutical compositions thereof. | 2013-09-12 |
20130236481 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. | 2013-09-12 |
20130236482 | AUGMENTATION OF TITER FOR VACCINATION IN ANIMALS - The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine. | 2013-09-12 |
20130236483 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY - The invention provides methods for increasing or decreasing antibody production in vivo by inhibiting or promoting the activity of fibroblast growth factor-2 (FGF2) respectively. | 2013-09-12 |
20130236484 | LEISHMANIASIS ANTIGEN DETECTION ASSAYS AND VACCINES - The present invention relates to isolated Visceral leishmaniasis (VL) antigens that are useful in therapeutic and vaccine compositions for stimulating a VL specific immunological response. The identified antigens are also useful in diagnostic assays to determine the presence of active VL in an individual. Combinations of antibodies raised against these antigens are especially useful in detection of VL infections. Accordingly, the present invention includes polypeptide molecules, nucleic acid molecules, vaccine compositions, diagnostic assays, and methods of diagnosis and monitoring treatment related to these VL antigens. | 2013-09-12 |
20130236485 | Somatic Stem Cells - A method of treating a cellular proliferative disorder in a subject by obtaining from a subject a bodily fluid sample containing a plurality of cells, incubating the sample with EDTA or heparin in a container until the sample is separated into an upper layer and a lower layer, collecting the upper layer, isolating from the upper layer a population of somatic stem cells that are 0.3-6.0 micrometers in size, differentiating the somatic stem cells to dendritic cells in a medium containing GCSF, SCF, EGF, PDGF, bFGF, and IL-3, purifying the dendritic cells, contacting the dendritic cells thus purified with a cancer antigen, and administrating an effective amount of the dendritic cells presenting the cancer antigen to a subject in need thereof. | 2013-09-12 |
20130236486 | IMMUNOGENIC VACCINE - A glycolipopeptide comprising a carbohydrate component, a lipid component, and a MUC1 peptide component that induces both a humoral and a cellular immune response for use as a therapeutic or prophylactic vaccine. | 2013-09-12 |
20130236487 | DESIGNER PEPTIDE-BASED PCV2 VACCINE - Porcine circovirus (PCV2) vaccine compositions comprising a peptide antigen derived from a PCV2 capsid protein are described. In various embodiments, the peptide antigen contains amino acids of the capsid protein from about amino acid 47 to about amino acid 202. In some embodiments, the peptide antigen is optionally linked to an artificial T helper epitope and/or mixed with T helper epitopes derived from the ORF1 and ORF3 proteins of PCV2. Methods of using PCV2 vaccine compositions are also described. In various embodiments, a vaccine composition is used in animals for the prevention of PCV2 infection. In other embodiments, a PCV2 vaccine composition is used as an antigen for diagnosing PCV2 infection. | 2013-09-12 |
20130236488 | PORPHYROMONAS GINGIVALIS POLYPEPTIDES USEFUL IN THE PREVENTION OF PERIODONTAL DISEASE - The invention is directed to vaccine compositions and methods based on | 2013-09-12 |
20130236489 | DEVELOPMENTS IN MENINGOCOCCAL OUTER MEMBRANE VESICLES - A first aspect of the invention provides meningococcal outer membrane vesicles in which NHBA is over-expressed. A second aspect of the invention provides meningococcal outer membrane vesicles in which NadA is over-expressed. A third aspect of the invention provides a panel of bacterial strains, each member of which is isogenic except for a single gene which in each strain encodes a different variant of an antigen of interest. | 2013-09-12 |
20130236490 | Multivalent Vaccine for Filariasis - The present invention is a multivalent vaccine for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent vaccine are protein-based, DNA-based, or a combination thereof. | 2013-09-12 |
20130236491 | SPHERICAL NANO AND MICROPARTICLES DERIVED FROM PLANT VIRUSES FOR THE DISPLAY OF FOREIGN PROTEINS OR EPITOPES - A novel type of particle platform for application in biotechnology is provided by the present invention. Said platforms comprise RNA-free particles generated by thermal denaturation and structural remodeling of helical plant viruses. Tobamovir-uses and, in particular, tobacco mosaic virus (TMV) coat protein (CP) subunits, denatured, at high temperatures are specifically self-assembled by two-stage assembly into the spherical particles (SPs) of similar shape and varying size including nanoparticles (SNPs) with a diameter up to 100-150 nm and spherical microparticles (SMPs) with a diameter up to 800 nm and more. The size of said SPs depends on the virus concentration used and, therefore can be controlled. Said SPs are biologically safe, highly stable and highly immunogenic. Said SNPs and SMPs are structurally distinct from viruses presently known. They are unique, having no protein nano-particle analogs in the nature. Said particles can be produced by the native virus and also by different forms of viral CP lacking RNA. The SPs can be generated by thermal denaturation and structural remodeling of different helical plant viruses belonging to genera | 2013-09-12 |
20130236492 | ADJUVANTED FORMULATIONS OF BOOSTER VACCINES - The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response. | 2013-09-12 |
20130236493 | METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES - The invention relates to methods of producing infectious bunyavirus replicon particles. These bunyavirus replicon particles are safe and can be used outside a biosafety containment. The invention further relates to recombinant bunyavirus replicon particles and uses of these recombinant bunyavirus replicon particles. | 2013-09-12 |
20130236494 | VACCINATION AGAINST INFLUENZA - Described are methods for vaccinating a subject against influenza comprising administering a vaccine multiple times to a subject where the vaccine comprises influenza hemagglutinin (HA) and neuraminidase (NA) proteins from at least a first influenza strain, wherein the HA and NA proteins of the first influenza strain are administered to the subject at least three times within a period of less than one year. Such immunization schemes induce cross-protection against heterologous and heterosubtypic influenza strains. | 2013-09-12 |
20130236495 | PEPTIDES FOR MODULATING T-CELL ACTIVITY AND USES THEROF - The present invention provides methods and materials for treating and preventing autoimmune diseases. In particular, the present invention relates to the discovery that small peptides are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD 154, which is important in inflammation. The present invention also relate to the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response. The present invention also relates to the use of such short peptides to prevent or reverse autoimmune disease, and particular, diabetes, in individuals suffering from such disease. It also relates to methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells. | 2013-09-12 |
20130236496 | USE OF LEUKOTRIENE B4 IN COMBINATION WITH A TOLL-LIKE RECEPTOR LIGAND, A RIG-I-LIKE RECEPTOR LIGAND, OR A NOD-LIKE RECEPTOR LIGAND TO ENHANCE THE INNATE IMMUNE RESPONSE - The present invention relates to the use of leukotriene B | 2013-09-12 |
20130236497 | TREATING NEOPLASMS WITH NEUROTOXIN - The present invention provides a method of treating a cancer using a neurotoxin, preferably Botulinum toxin (“BTX”). The application of a neurotoxin around a cancer acts to decrease the contractile forces of the muscles surrounding a neoplasm which normally squeeze cancer cells through efferent channels leaving the cancer vicinity to distant sites. Also, the application of the toxin at sites distant from the cancer enhances cellular and humoral immunologic functions which further contributes to cancer cell death and spread. Following administration of botulinum toxin around and distant to a cancer, it is noticed that local, regional, and distant spread is reduced or eliminated. Immunomodulation with botulinum toxin is also valuable in treating other disease that may or may not be associated with cancers, such as viral-induced growths, viral conditions, fungal disease, chronic wounds, graft versus host disease, autoimmune disease, and HIV. | 2013-09-12 |
20130236498 | BIODEGRADABLE SUPPORTING DEVICE - A biodegradable in vivo supporting device is disclosed. The in vivo supporting device comprises a biodegradable metal scaffold and a biodegradable polymer coating covering at least a portion of the biodegradable metal scaffold, wherein the biodegradable polymer coating has a degradation rate that is faster than the degradation rate of the biodegradable metal scaffold. | 2013-09-12 |
20130236499 | Segmented, Semicrystalline Poly(Lactide-co-epsilon-Caprolactone) Absorbable Copolymers - Novel semi-crystalline, segmented copolymers of lactide and epsilon-caprolactone exhibiting long term absorption characteristics are disclosed. The novel polymer compositions are useful for long term absorbable meshes, surgical sutures, especially monofilament sutures, and other medical devices. | 2013-09-12 |
20130236500 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 2013-09-12 |
20130236501 | Injectable Emulsion of Sedative Hypnotic Agent - The present invention provides novel pharmaceutical formulations of a substituted phenylacetic acid ester compound, which is useful as a short-acting sedative hypnotic agent for anesthesia and sedation. The pharmaceutical formulations are oil-in-water emulsions suitable for administration by injection. The invention further provides processes for the preparation of the formulation and the use of the formulation in medical treatment of a mammal. | 2013-09-12 |
20130236502 | IMPLANTABLE MEDICAL DEVICES HAVING MICROPOROUS SURFACE LAYERS AND METHOD FOR REDUCING FOREIGN BODY RESPONSE TO THE SAME - This disclosure provides implantable devices coated with microporous surface layers with macrotopographic features that improve bio-integration at the interface of the implantable devices and the surrounding tissue. | 2013-09-12 |
20130236503 | SCAFFOLD FOR GROWING NEURONAL CELLS AND TISSUE - The present invention provides a composition based on poly- | 2013-09-12 |
20130236504 | Delivery System for Enhancing Drug Efficacy - Disclosed are delivery systems that can be used for treating cancer. The delivery systems include a delivery vehicle in conjunction with a chemo-adjuvant. The chemo-adjuvant can enhance the efficacy of a therapeutic agent that can be delivered in conjunction with the delivery vehicle or can be delivered independently of the delivery vehicle. | 2013-09-12 |
20130236505 | Production Of Pharmaceutical Protective Coatings With Good Resistance In A Neutral Environment - Pharmaceutical coatings obtained from coating compositions based on film-forming copolymers of N,N-diethylaminoethyl methacrylate (DEAEMA) and methyl methacrylate (MMA) comprising a weight ratio of DEAEMA:MMA in the range of 35:65 to 55:45, where the copolymers are present partially neutralized with C | 2013-09-12 |
20130236506 | AMNION AND CHORION CONSTRUCTS AND USES THEREOF IN OB-GYN SURGERY - A construct for use in an OB/GYN surgery is described. The construct contains an allograft having at least one layer of human amnion and chorion tissues, and has a size and shape appropriate for covering an incision or a surgical site resulting from the surgery. Methods of preparing the construct and using it in an OB/GYN surgery are also described. The products and methods improve the performance of the OB/GYN surgery, e.g., by reducing adhesions, scar formation while also reducing inflammation and risk of post-operative infection. | 2013-09-12 |
20130236507 | Method for treating cancer by using Fe-containing alloy particles - A method for treating a cancer is disclosed, which comprises: administering an effective amount of Fe-containing alloy particles to a subject in need, wherein a material of each Fe-containing alloy particle is an alloy comprising a first metal of Fe and a second metal. | 2013-09-12 |
20130236508 | METHOD OF TREATMENT - The method relates to a method of treating proteinuria comprising administering lactoferrin. | 2013-09-12 |
20130236509 | MICROPARTICLES COMPRISING A SMALL HEAT-SHOCK PROTEIN - The invention relates to a biodegradable microparticle having a diameter between 0.2 and 3.5 micrometer and comprising a pharmaceutically effective amount of at least one small heat-shock protein that induces IL-10 production in macrophages, said small heat-shock protein comprising an amino acid sequence identity of at least 50% to any of the sequences listed as SEQ ID NOs: 1 and 12-26. | 2013-09-12 |
20130236510 | MULTIPLEXED SUPRAMOLECULAR ASSEMBLIES FOR NON-VIRAL DELIVERY OF GENETIC MATERIAL - The invention provides a composition comprising two or more of a) genetic material; b) a condensing agent; c) a membrane destabilizing agent; d) a targeting/stabilizing agent, and optionally e) an ionic cross-linking agent. The components of the composition can self-assemble to form particles via electrostatic and/or lipophilic interactions. Methods of making and using the composition are also provided. The compositions can be used, for example, to transfer genetic material to cells in vitro or in vivo. | 2013-09-12 |
20130236511 | FORMULATION AND MANUFACTURE OF PHARMACEUTICALS BY IMPREGNATION ONTO POROUS CARRIERS - The present invention provides methods for impregnating a porous carrier with an active pharmaceutical ingredient (“AP”), the methods comprising steps: a) dissolving at least one API in a solvent to form an API solution; b) contacting a porous carrier with the at least one API of step (a) in a contactor to form an API impregnated porous carrier; and c) drying the at least one API impregnated porous carrier. | 2013-09-12 |
20130236512 | NOVEL CELLULOSE ETHERS AND THEIR USE - Cellulose ethers are described herein which are useful in capsules or in coatings for dosage forms. In these cellulose ethers the ether substituents are methyl groups, hydroxyalkyl groups, and optionally alkyl groups being different from methyl, the cellulose ether has an MS (hydroxyalkyl) of 0.05 to 1.00, and hydroxy groups of anhydroglucose units are substituted with methyl groups such that [s23/s26−0.2*MS(hydroxyalkyl)] is 0.35 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 3-positions of the anhydroglucose unit are substituted with methyl groups and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 6-positions of the anhydroglucose unit are substituted with methyl groups. | 2013-09-12 |
20130236513 | Synthetic Polyurethane Composite - Embodiments of the present inventions comprise composites of polyurethane(s), osteoconductive matrix, and, optionally, a growth factor. Embodiments further comprise methods of making such composite and uses thereof. The osteoconductive matrix can be a tricalcium phosphate, bioglass, or the like, and can include particles that are surface modified. Growth factors can be provided in powder form, including bone morphogenic proteins such as rhBMP-2. A composition may be moldable and/or injectable. After implantation or injection, a composition may be set to form a porous composite that provides mechanical strength and supports the in-growth of cells. | 2013-09-12 |
20130236514 | Pharmaceutical Compositions Comprising Terbinafine - This invention provides a terbinafine pharmaceutical composition which is emulsifable or self-emulsifying or in form of an emulsion wherein the composition is adapted for oral administration. | 2013-09-12 |
20130236515 | LEVALBUTEROL SALT - Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler. | 2013-09-12 |
20130236516 | Felbinac-Containing External Patch - Provided is a felbinac-containing external patch which can exhibit high drug release properties, low skin irritation, and high drug stability, wherein felbinac having an average particle diameter of 5 μm or more and less than 100 μm is dispersed and mixed in an adhesive base including a styrene-isoprene-styrene block copolymer, an alicyclic saturated hydrocarbon resin, a softener, and diethyl sebacate, and does not contain L-menthol. Specifically, in the felbinac-containing external patch, 0.1 to 10% by weight of felbinac having an average particle diameter of 5 μm or more and less than 100 μm is dispersed and mixed in an adhesive base including 10 to 30% by weight of a styrene-isoprene-styrene block copolymer, 10 to 50% by weight of an alicyclic saturated hydrocarbon resin, 10 to 75% by weight of a softener, and 0.1 to 10% by weight of diethyl sebacate. | 2013-09-12 |
20130236517 | Apatite Forming Biomaterial - The present invention relates to chemically bonded ceramic biomaterials, especially a dental material or an implant material. The main binder system forms a chemically bonded ceramic upon hydration thereof, and comprises powdered calcium aluminate and/or calcium silicate, and phase(s) to secure apatite formation at a pH close to neutrality. A second binder system—a cross-linking organic binder system which provides for initial crosslinking of the freshly mixed paste is advantageously added. The invention relates to a powdered composition for preparing the inventive chemically bonded ceramic biomaterial, and a paste from which the biomaterial is formed, as well as a kit comprising the powdered composition and hydration liquid, as well as methods and use of the biomaterial in dental and implant applications with the aim of remineralisation, integration and bone repair. | 2013-09-12 |
20130236518 | MATERIALS AND METHODS FOR DELIVERING COMPOSITIONS TO SELECTED TISSUES - This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics. | 2013-09-12 |
20130236519 | Oral health care material and teeth cleaning agent composition - An oral health care material and a teeth cleaning agent composition are disclosed. The oral health care material is made of zinc oxide grains, where each is selected from the group consisting of zinc oxide crystalline nanograins, zinc oxide nanorods, zinc oxide hollow fibers, and a mixture thereof, wherein the diameter of each of the zinc oxide crystalline nanograins is 25 nm-200 nm, the cross-sectional diameter of each of the zinc oxide nanorods is 50 nm-1000 nm, the cross-sectional diameter of each of the zinc oxide hollow fibers is 500 nm-3 μm and its nanograin size is 20 nm-100 nm. | 2013-09-12 |
20130236520 | Infused Sponge Delivery System - A method for delivering active ingredients to a wet substrate from a flexible, three-dimensional, water-absorbent substrate material comprised of a web of substantially water-insoluble fibers into which is infused a solid anhydrous composition having a melting point of from about 45° C. to about 55° C. said anhydrous composition comprising (i) at least one surfactant selected from the group consisting of cationic quaternary surfactants, anionic surfactants or nonionic surfactants or one multi-lamellar liquid crystal emulsifier system, (ii) at least one fatty alcohol, (iii) at least one emollient selected from the group consisting of cosmetically-acceptable oils, esters and liquid triglycerides, (iv) at least one active ingredient and (v) optionally, a solid cleansing agent having a melting point from about 50° C. to about 70° C. Preferred active ingredients are skincare and haircare actives, including emollients, humectants, conditioning agents, sunscreens and sunblocks, and artificial tanning agents. | 2013-09-12 |
20130236521 | SnF2 APPLICATIONS, METHODS AND RELATED FORMULATIONS - The present disclosure is directed to method of treating a herpes virus. In one embodiment, the method includes adding an effective amount of stannous fluoride (SnF | 2013-09-12 |
20130236522 | MICROBIAL PESTICIDAL COMPOSITION | 2013-09-12 |
20130236523 | Antipathogenic Surfaces Having Selenium Nanoclusters - The present invention is directed to methods for inhibiting growth of pathogens and to substrates with selenium nanoparticles or selenium nanoclusters having antipathogenic properties. | 2013-09-12 |
20130236525 | Sustained release intraocular implants and related methods - Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years. | 2013-09-12 |
20130236526 | Sustained Release Intraocular Implants and Methods for Preventing Retinal Dysfunction - Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like. | 2013-09-12 |
20130236527 | LICORICE LOLLIPOP THAT INHIBITS DENTAL CARIES FORMATION - This invention pertains to the discovery that certain extracts of licorice, particularly when formulated as a candy or lollipop or other means that provides an extended release (e.g., greater than about 4 minutes) to the oral cavity significantly inhibits the formation of dental caries in a human subject. | 2013-09-12 |
20130236528 | ALLERGEN INHIBITOR, ALLERGEN-INHIBITING PRODUCT, ALLERGEN INHIBITING METHOD, AND USE AS ALLERGEN INHIBITOR - The present invention provides an allergen inhibitor which effectively prevents allergens from reacting with specific antibodies, mitigates the allergic symptoms or prevents appearance thereof, and is less likely to cause unpredictable discoloration and discoloration under usual conditions. The allergen inhibitor of the present invention comprises an allergen-inhibiting compound including a linear polymer having at least one of substituents represented by the formulas (1) to (3) at a side chain. Thus, the allergen inhibitor of the present invention shows excellent allergen-inhibiting effects. | 2013-09-12 |
20130236529 | COMPOSITION AND METHODS TO ENHANCE ANTI-OXIDATION, GUT FLORA AND IMMUNITY IN PETS - The presented composition and methods are effective to enhance anti-oxidation, gut flora and immune stimulation in pets. The composition includes a combination of Dihydroquercetin and Siberian or Dahurian Larch Arabinogalactan, more specifically, wherein the Larch Arabinogalactan has a molecular weight between about 9.5 kDa and about 37 kDa. The compositions may be in the form of a tablet, chewable tablet, capsule, resin, oil, liquid, liposome, powder, or suppository, and may be further comprised of a pharmaceutically acceptable carrier; or may be incorporated into a bulk feed or a feed supplement. | 2013-09-12 |
20130236530 | PAIN RELIEVER COMPOSITION - A pain reliever comprised of dextrose, | 2013-09-12 |
20130236531 | PHARMACEUTICAL COMPOSITION INCLUDING AN HIF-2 ALPHA INHIBITOR AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING ARTHRITIS - The present invention relates to a pharmaceutical composition for preventing or treating arthritis, including, as an active ingredient, a material which inhibits the expression of the hypoxia-inducible factor-2α (HIF-2α) gene or the activity of the HIF-2α protein. According to the present invention, the HIF-2α of the present invention increases the expression thereof in chondrocytes or tissue in which osteoarthritis is induced, and triggers the expression of various cartilage degeneration factors and the activation of mitogen-activated protein (MAP) kinase. In addition, when HIF-2α is inhibited, the expression level of cartilage degeneration factors and the phosphorylation of MAP kinase are significantly reduced by the inhibited degree of HIF-2α. Thus, the composition of the present invention may be applied to the prevention or treatment of arthritis, and may be used for the development of therapeutics for arthritis. | 2013-09-12 |
20130236532 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES - The present application discloses compositions and methods useful for treating and preventing inflammation associated with inflammatory diseases and disorders. | 2013-09-12 |
20130236533 | Vaccine Nanotechnology - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at last one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof. | 2013-09-12 |
20130236534 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES - Drug derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drug derivatized with a weak-base moiety that facilitates active loading of the drug through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drug to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drug derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drugs. | 2013-09-12 |
20130236535 | Antibodies - The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields. | 2013-09-12 |
20130236536 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein - Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2′-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible to aberrant hypermethylation. Such analogues can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position. Methods for synthesizing these oligonucleotide analogues and for modulating nucleic acid methylation are provided. Also provided are phosphoramidite building blocks for synthesizing the oligonucleotide analogues, methods for synthesizing, formulating and administering these compounds or compositions to treat conditions, such as cancer and hematological disorders. | 2013-09-12 |
20130236537 | Pharmaceutical preparation for tumor chemotherapy and method for producing the same - The present invention provides a pharmaceutical preparation for tumor chemotherapy and a method for producing the same, the pharmaceutical preparation for tumor chemotherapy comprises cell vesicles derived from apoptotic tumor cells and chemotherapeutic drugs as active ingredients wrapped within the cell vesicles. The chemotherapeutic drugs contained within the pharmaceutical preparation are chemotherapeutic drugs containing active ingredients for the treatment of the tumors from which the cell vesicles are provided. The present invention also provides a method for producing the pharmaceutical preparation for tumor chemotherapy. The technical solutions provided by the present invention can selectively release the chemotherapeutic drugs to the tumor sites and maintain lasting medicinal effect, increasing their killing effects against tumor cells and reducing the toxic side-effect of the chemotherapeutic drugs to normal cells. | 2013-09-12 |
20130236538 | PHARMACEUTICAL COMPOSITIONS OF IBUPROFEN AND FAMOTIDINE - Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. In some embodiments, the ibuprofen is in direct physical contact with the famotidine. | 2013-09-12 |
20130236539 | METHOD OF REDUCING SOMNOLENCE IN PATIENTS TREATED WITH TIZANIDINE - An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution. | 2013-09-12 |
20130236540 | ORAL DOSAGE FORM OF 25-HYDROXYVITAMIN D - Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D | 2013-09-12 |
20130236541 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER - The present invention relates to a combination comprising a substance with inhibiting effect on the ileal bile acid transport system (I BAT) and at least one other active substance selected from an IBAT inhibitor; an enteroendocrine peptide or enhancer thereof; a dipeptidyl peptidase-IV inhibitor; a biguanidine; an incretin mimetic; a thiazolidinone; a PPAR agonist; a HMG Co-A reductase inhibitor; a bile acid binder; and a TGR5 receptor modulator; wherein the IBAT inhibitor compound and the at least one other active substance are administered simultaneously, sequentially or separately. | 2013-09-12 |
20130236542 | SLOW RELEASE MAGNESIUM COMPOSITION AND USES THEREOF - The present invention provides compositions that contain magnesium and threonate, or a threonate precursor molecule, formulated for extended or modified release to provide physiological concentrations over a desired time period. The extended release or modified release form is particularly useful in providing Mg to a subject while avoiding adverse side effects such as diarrhea. | 2013-09-12 |
20130236543 | PHARMACEUTICAL COMPOSITION AND USES THEREOF - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases. | 2013-09-12 |
20130236544 | STABLE PHARMACEUTICAL COMPOSITIONS OF FESOTERODINE - The present invention relates to stable pharmaceutical compositions comprising fesoterodine or a pharmaceutically acceptable salt thereof. In particular, the invention relates to pharmaceutical compositions of fesoterodine or a pharmaceutically acceptable salt thereof and a stabilizer. The invention also relates to processes for making such compositions and the methods of using such compositions. | 2013-09-12 |
20130236545 | PHARMACEUTICAL COMPOSITION COMPRISING CITRATE AND BICARBONATE SALTS, AND USE THEREOF FOR TREATING CYSTINURIA - A solid oral pharmaceutical composition in the form of tablets including:—a first solid oral pharmaceutical formulation in the form of at least one micro-tablet, the micro-tablet consisting of a core including at least one Krebs cycle precursor salt as active ingredient, and of a coating including at least one coating agent, and—a second oral pharmaceutical formulation in the form of at least one mini-tablet, the mini-tablet consisting of a core including at least one bicarbonate salt as active ingredient and at least one prolonged-release matrix, and of a coating including at least one coating agent. The use thereof as a medicament, in particular in the treatment and/or prevention of cystinuria. | 2013-09-12 |
20130236546 | THYME/PRIMROSE OR IVY FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) - The invention relates to an extract made of thyme ( | 2013-09-12 |
20130236547 | POLYURETHANES FOR OSTEOIMPLANTS - Biological-based polyurethanes and methods of making the same. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an osteoimplant. | 2013-09-12 |
20130236548 | Method for treating cancer by using Fe-based particles - A method for treating a cancer is disclosed, which comprises: administering an effective amount of Fe-based particles to a subject in need, wherein the Fe-based particles have core-shell structures. Herein, each Fe-based particle of the present invention comprises: an Fe elemental core with zero valent irons; and a covering layer formed on partial or whole surface of the Fe elemental core, wherein a material of the covering layer is a metal, a metal doped with dopants, a metal alloy, a polymer, carbon, a metal oxide or a nonmetal oxide, and the shape of the Fe-based particles is a rod, a sphere, a cubic or a dumbbell, with the proviso that the metal is not Au. | 2013-09-12 |
20130236549 | TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT - An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea. | 2013-09-12 |
20130236550 | PHARMACEUTICAL MICROPARTICLES - Microparticles consisting of (a) a matrix with a mixture of (a | 2013-09-12 |
20130236551 | COMBINATION COMPOSITION USEFUL FOR TREATING CARDIOVASCULAR DISEASES - It is described the use of a combination consisting of a microcapsule suspension comprising one or more statins in alkyl esters of n-3 PUFA in which the statins are isolated from contact with the alkyl ester of n-3 PUFA by means of a polymeric membrane that can be easily disintegrated in the gastrointestinal medium, for the treatment of cardiovascular diseases. | 2013-09-12 |
20130236552 | NANOTOPOGRAPHY-MEDIATED REVERSE UPTAKE PLATFORM FOR NUCLEIC ACID DELIVERY AND APPLICATIONS THEREOF - This application discloses a nanotopography-mediated reverse uptake (NanoRU) platform useful for intracellular delivery of nucleic acids into mammalian cells, in particular stem cells, as well as methods of preparation and applications thereof. In particular, this system can be used to deliver small interfering ribonucleic acids (siRNAs) into neural stem cells and enhance neuronal differentiation of the stem cells. | 2013-09-12 |
20130236553 | Compositions and Methods for the Delivery of Therapeutics - The present invention provides compositions and methods for the delivery of therapeutics to a cell or subject. | 2013-09-12 |
20130236554 | DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME - The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms. | 2013-09-12 |
20130236555 | ORGANIC POLYMERIC PHOTON UP-CONVERSION NANOPARTICLES FOR BIOLOGICAL APPLICATIONS - The present invention relates to organic polymeric photon up-conversion nanoparticles for biological applications, such as labeling and/or detection of cells, biological (macro-) molecules or other analytes, as well as for sensing temperature, pressure, oxygen and other substances that influence the up-conversion process. It further relates to organic photon up-conversion nanoparticles for singlet oxygen generation and the treatment of diseases, such as cancer. | 2013-09-12 |
20130236556 | COMPOSITIONS AND METHODS RELATING TO REDUCED MUCOADHESION - The present invention generally relates to reducing the mucoadhesive properties of a particle. In some embodiments, the particle is coated with and/or associated with a (poly(ethylene glycol))-(poly(propylene oxide))-(poly(ethylene glycol)) triblock copolymer. Methods for preparing inventive particles using a poly(ethylene glycol)-vitamin E conjugate as a surfactant are also provided. In some embodiments, methods are provided comprising administering to a subject a composition of particles of the present invention. Such particles with reduced mucoadhesive properties are useful in delivering agents to mucosal tissues such as oral, ophthalmic, gastrointestinal, nasal, respiratory, and genital mucosal tissues. | 2013-09-12 |
20130236557 | Oil-in-Oil emulsified polymeric implants containing a hypotensive lipid and related methods - Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the ploymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma. | 2013-09-12 |